Send to

Choose Destination
Am J Clin Oncol. 2002 Feb;25(1):45-7.

Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study.

Author information

Department of Reproductive Medicine, Division of Gynecologic Oncology, University of California-San Diego Medical Center, 402 Dickinson Street, San Diego, CA 92103-8433, U.S.A.


The Gynecologic Oncology Group performed a Phase II study to determine the response rate of pyrazoloacridine (PZA) in patients with platinum-resistant ovarian cancer. PZA was administered at a dose of 750 mg/m2 intravenously over 3 hours every 3 weeks. Among 24 evaluable patients, there was 1 (4.2%) complete and 1 (4.2%) partial response. The major toxicities were hematologic. With the dose and schedule used, PZA had only modest activity in this population.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center